We are pleased to announce that the virtual 15th Annual European Life Sciences CEO Forum (ELSF) will take place on the 1st-2nd of March 2022 and be part of the digital Sachs Spring Life Sciences Week, that will also incorporate the 3rd Annual European HealthTech CEO Forum.

Back for its 15th Annual Edition, this global bio-pharma industry event will address the main challenges for 2022, including investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors.

The main programme for the 15th Annual ELSF is spread throughout 2 days (1st-2nd of March) and will include BioCapital & Investment Day and Bio-Pharma Partnering & Therapeutics Day. The two days will feature more than 12 hours of high-level speeches and panel discussions. In addition, there will be 45+ presentations by globally established public, private, emerging and seed companies who offer innovation solutions and are seeking investment and partnering opportunities. We anticipate 400+ delegates will register for the forum from all Life Sciences sectors, with the target audience being corporate and financial investors/partners, bankers and advisors.

The virtual meetings will take place from the 28th February to 4th of March. Moreover, the system will be open for 12 hours a day and we expect 1500+ meetings completed over 5 days. The conference will be held in the Central European Time Zone. The digital event will consist of:

BioCapital & Investment Day (Tuesday, 1st of March)

• State of the Industry Panel
• Pandemic Response Panel
• VC, Private Equity Funds Panel
• Platform Technologies & Novel Therapeutics Panel
• Biotech Capital Markets Panel
• Advances in Gene & Cell Therapies Panel
• Early Stage Innovation & Investment Panel
• Rising Stars Session

Bio-Pharma Partnering & Therapeutics Day (Wednesday, 2nd of March)

• China BioPartnering & Investment: Bringing Chinese Innovation to Global Markets Panel
• Pharma M&A and Partnering Panel
• Immuno-Oncology BD & Partnering Panel
• Advances in Immuno-Oncology Panel
• Recent Advances in Alzheimer’s & Other Neurodegenerative Disorders Panel
• Biotech Meets FoodTech Panel

Online Virtual Meetings (28th February – 4th of March)

• Alexandre Bastos, Head of Front End Innovation, Givaudan
• Andrea Carfi, Chief Scientific Officer, Infectious Disease, Moderna, Inc.
• Andreas Hohn, Director of Transaction Excellence, Roche Partnering, F. Hoffmann-La Roche Ltd.
• Andrew Allen, Co-Founder, President & CEO, Gritstone Bio, Inc.
• Aram Mangasarian, CEO, NOXXON Pharma NV
• Bibhash Mukhopadhyay, Founder & Managing Partner, Sound Bioventures Management AB
• Christina Hertel, Senior Program Manager – Gold Track, EIT Health e.V.
• Corinne Venot, Executive Director, Business Development, BeiGene Ltd.
• Daniel Teper, Co-Founder, Chairman & CEO, Cytovia Therapeutics Inc.
• Diana Saraceni, Co-Founder & General Partner, Panakès Partners SGR SpA
• Didier Toubia, Co-Founder, CEO of Aleph Farms
• Duncan Young, Senior Director, Search & Evaluation, Oncology R&D, AstraZeneca
• Emmanuelle Coutanceau, Partner, Novo Seeds, Novo Holdings A/S
• Eric Halioua, President & CEO, PDC*line Pharma SA
• Esteban Pombo-Villar, CTO, TargImmune Therapeutics AG
• Fintan Walton, Founder & CEO, PharmaVentures Ltd.
• Fiona Choppe Magal, Partner, Cukierman & Co. Investment House, FoodTech & Agritech
• Florian Schödel, Owner, Philimmune, LLC
• Gabriel Cavazos, Senior Managing Director, Investment Banking, SVB Leerink
• George Frodsham, Founder & CEO, MediSieve
• Gil Bar-Nahum, Managing Director, EMEA Head of Biotechnology, Jefferies International Ltd.
• Gregor Macdonald, VP, Head of BD & Licensing, Search & Assessment, H. Lundbeck A/S
• Hany Awadalla, Managing Director & Head of Investment Banking, LifeSci Capital LLC
• Hubert Birner, Managing Partner, TVM Life Science Management GmbH
• Holger Kissel, Vice President Business Alliances, BioNTech SE
• Ilan Sobel, CEO, BioHarvest Sciences Inc.
• Jan de Kerpel, Managing Director, Head of Life Sciences & Healthcare Kempen & Co
• Juan Carlos Jaramillo, Chief Medical Officer, Valneva SE
• Kaare Engkilde, CEO, Amniotics AB
• Katya Smirnyagina, Senior Partner for Life Sciences, Oxford Sciences Innovation
• Kay Penicud, Director of Innovation and Business, UK Dementia Research Institute
• Khatereh Ahmadi, Head of Search & Evaluation Business Development, Europe & Middle East, MSD
• Kylor Hua, Executive Director, Torreya
• Lynn Durham, Founder & CEO, STALICLA SA
• Marietta Wu, Managing Director, Quan Capital
• Matthias Müllenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA
• Max Herrmann, Head of UK Healthcare Equity Research, Stifel Financial Corp.
• Meredith Fisher, Partner, Mass General Brigham Ventures
• Michael Altorfer, CEO, Swiss Biotech Association
• Michael Cozart, Managing Partner, LifeSci Consulting
• Michael Friedrich, CEO, Distalmotion SA
• Michael Margolis, Senior Managing Director, Co-Head, Healthcare Investment Banking, Oppenheimer & Co. Inc
• Michael Rice, VP, Head of Advanced Therapeutics & Rare Diseases, Cello Health BioConsulting
• Miguel Forte, CEO, Bone Therapeutics SA
• Mike Romanos, Co-Founder & CEO, Microbiotica Ltd.
• Mythili Koneru, CMO, Marker Therapeutics, Inc.
• Nanna Lüneborg, General Partner, Forbion
• Narender Mantena, CEO, Biological E Limited
• Nathalie ter Wengel, European Lead, Worldwide Business Development, Pfizer, Inc.
• Nicholas Franco, EVP & Chief Business Development Officer, Allschwil Site Head, Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson
• Nicholas Moore, Managing Director, Healthcare Investment Banking, Stifel Nicolaus Europe Limited
• Niels Emmerich, VP, Global Head Search & Evaluation, AbbVie, Inc.
• Paul Hermant, Partner, Bird & Bird LLP
• Peter Llewellyn-Davies, CEO/CFO, invIOs GmbH
• Priyanka Belawat, Investment Advisor Private Equity, HBM Partners AG
• Rainer Strohmenger, Managing Partner, Wellington Partners Life Sciences (WPLS)
• Reagan Jarvis, CEO, Anocca AB
• Renee Aguiar-Lucander, CEO, Calliditas Therapeutics AB
• Robert de Jonge, VP Head of Corporate Development, Mestag Therapeutics Ltd.
• Ros Deegan, CEO, OMass Therapeutics
• Ryan Richardson, Chief Strategy Officer, BioNTech SE
• Sam Fazeli, Head of Research, Senior Pharmaceuticals Analyst, Bloomberg Intelligence
• Sascha Berger, General Partner, TVM Life Science Management GmbH
• Sandra Ferri, Head of Life Sciences Investments, European Investment Fund
• Sarah Holland, CBO, VectivBio AG
• Shafique Virani, Chief Corporate Development Officer, Recursion, Inc.
• Søren Møller, Managing Partner, Novo Holdings A/S
• Speaker TBA, BeiGene Ltd.
• Stephanie Léouzon, Partner & Head of Europe, Torreya
• Stephen Myatt, CEO, Macomics Ltd.
• Steve Rees, Vice President of Discovery Biology, AstraZeneca
• Theodora Harold, CEO, Crescendo Biologics Ltd.
• Thibaut Roulon, Senior Investment Director, Bpifrance
• Thijs Cohen Tervaert, Junior Partner, INKEF Capital BV
• Thomas Roth, CEO, Inzipio GmbH
• Thomas Shrader, Managing Director & Healthcare Analyst, BTIG, LLC
• Tim Dyer, Co-Founder, Board Director & CEO, Addex Therapeutics Ltd.
• Tim Haines, Chairman & Managing Partner, Abingworth LLP
• Tim Luker, VP Venture Science, Corp BD, Eli Lilly and Company
• Volker Germaschewski, SVP R&D, eTheRNA immunotherapies NV
• Yonatan Golan, CEO, Brevel Ltd.